VCU Massey Cancer Center

Menu

Massey member directory

For members: update your profile »

« Back to member list

Anindita Das, M.S., Ph.D.

Research program member: Cancer Molecular Genetics

Box 980204
1101 E. Marshall St.
Richmond, VA 23298-5048

804-628-5519

Email: anindita.das@vcuhealth.org

Affiliations

Associate Professor, Internal Medicine, School of Medicine

Education

PhD, University of Jadavpur, India (1997)
MS, University of Kalyani, India (1988)

Research description

I am interested in developing novel therapeutics that could selectively inhibit doxorubicin-induced cardiotoxicity but not tumoricidal activity. Previously, we showed that treatment with sildenafil and tadalafil (specific inhibitors of phosphodiesterase 5) prior to doxorubicin-treatment prevented cardiomyocyte apoptosis and improved cardiac function in the animals. Pre-clinical studies from our laboratory suggested that co-treatment with sildenafil potentiates antitumor efficacy of doxorubicin, while ameliorated doxorubicin-induced cardiotoxicity. Similarly, rapamycin, a selective inhibitor of mTOR, has been shown to protect against myocardial infarction and heart failure. mTORC1 signaling is hyperactive in the majority of cancers. Thus, inhibiting mTORC1 signaling has attracted great attention as an anti-cancer therapy. Considering the potent cardioprotective effects of sildenafil and rapamycin, we are interested in investigating the effect of combination treatment with these drugs whether these would protect heart against doxorubicin-induced cardiotoxicity while enhancing its antitumor activity.

Research keywords

Cardiotoxicity, myocardial ischemia/reperfusion, mTOR, PDE5, miRNA

Published research

Search In PubMed